Important Dates

  • Registration Opens: Apr 17, 2017
  • Abstract Submission Opens: May 8, 2017 
  • Abstract Submission Closes: Jun 22, 2017, 5:00 p.m. ET 
  • Early Bird Registration Deadline: Jul 27, 2017
  • Hotel Reservation Deadline: Aug 15, 2017 

ASM Co-Chair

Keith Rodvold, Pharm.D., FCCP, FIDSA
Colleges of Pharmacy and Medicine
University of Illinois at Chicago
Chicago, IL

ESCMID Co-Chair 

William Hope, BMBS, FRACP, FRCPA, PhD
University of Liverpool
United Kingdom 

Program Committee Members


Follow #ASMESCMID on Twitter for the latest updates on this meeting! 

Program by Day

Tuesday, September 5, 2017 

1:00 p.m. – 5:00 p.m.
Complimentary Pre-Conference Workshop: Antibiotic Development Bootcamp – Sponsored by CARB-XED, GARDP, ASM, and ESCMID
(Bootcamp series continues Thursday with the Clinical Microbiology for a Development Program session) 

1:00 p.m. – 3:00 p.m.
Decisions, Decisions: What Makes a Good Hit? A Good Lead? Why Do You Write a TPP? How Do You Write a TPP?
Moderator: Lynn Silver, LL Silver consulting, LLC

3:00 p.m. – 5:00 p.m.
Chemistry, Manufacturing, and Controls: How Does a Molecule Become a Physical Medicine to be Given to a Human
Moderator: Tim Keutzer, Spero Therapeutics

6:00 p.m. – 8:00 p.m.
Reception

Wednesday, September 6, 2017 

7:30 a.m. – 8:00 a.m.
Light Breakfast

8:00 a.m. – 8:15 a.m. 
Opening Remarks
ASM and ESCMID Leadership

Keynote Lecture
8:15 a.m. – 8:45 a.m. 
Challenge of Antimicrobial Resistance in 2017
Yohei Doi
, University of Pittsburgh, Center for Care of Infectious Diseases

Regulatory Pathways for AMR and Technology Appraisal Process

8:45 a.m. - 9:15 a.m.
EMA Updates and Perspectives
Marco Cavaleri, European Medicines Agency

9:15 a.m. - 9:45 a.m.
FDA Updates and Perspectives
Sumathi Nambiar, Food and Drug Administration

9:45 a.m. - 10:15 a.m.
Technology Appraisal Process of New Antibiotics
Colm Leonard, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence

10:15 a.m. - 10:45 a.m.
Coffee Break

Strategies and Experiences in Accelerated Drug Development Programs

10:45 a.m. - 11:15 a.m.
Ceftazidime-Avibactam
David Melnick, Allergan

11:15 a.m. - 11:45 a.m.
Plazomicin
Ian Friedland, Achaogen

11:45 a.m. - 12:15 p.m.
Meropenem-Vaborbactam
Michael Dudley, Rempex Pharmaceuticals

12:15 p.m. - 12:45 p.m.
Roundtable Discussion

12:45 p.m. - 1:45 p.m.
Lunch

Challenges with Clinical Trial Design and Funding Issues

1:45 p.m. - 2:15 p.m.
Pathogen-Specific Agent for Pseudomonas aeruginosa
Andreas Wallnoefer, BioMed Partners AG

2:15 p.m. - 2:45 p.m.
Targeting a Single Species: Acinetobacter baumannii
Robin Isaacs, Entasis Therapeutics

2:45 p.m. - 3:15 p.m.
Old Drug/New Formulation for Europe: Minocycline
Jeff Loutit, Rempex Pharmaceuticals

3:15 p.m. - 3:45 p.m. 
Old Drug/New Formulation for USA: Fosfomycin 
Evelyn J. Ellis-Grosse, Zavante Therapeutics

3:45 p.m. - 4:45 p.m.
Coffee Break / Poster Presentations 

AMR, Regulatory Science, and Drug Development

4:45 p.m. - 5:00 p.m.
Platform Research Presentation

5:00 p.m. - 5:15 p.m.
Platform Research Presentation

5:15 p.m. - 5:30 p.m.
Platform Research Presentation

5:30 p.m. – 6:30 p.m.
Reception

Thursday, September 7, 2017

7:30 a.m. – 8:00 a.m.
Light Breakfast

Keynote Lecture
8:00 a.m. - 8:30 a.m.
Global Priority List of AMR and 2017 Essential Medicine List
Nicola Magrini
, World Health Organization

Strategic Action Plans on Antibiotic Research and Development for AMR

8:30 a.m. - 9:00 a.m.
Global Union for Antibiotics Research and Development (GUARD)
Selma Stern, Boston Consulting Group

9:00 a.m. - 9:30 a.m.
Update on CARB-XED and DRIVE AB Final Conference
John Rex, F2G Ltd, CARB-X, Wellcome Trust, Advent Life Sciences

9:30 a.m. - 10:00 a.m. 
International Models and Funding
Tim Jinks
, Wellcome Trust

10:00 a.m. - 10:30 a.m. 
Coffee Break

Clinical Microbiology for a Development Program – Sponsored by CARB-XED, GARDP, ASM, and ESCMID

10:30 a.m. - 11:00 a.m.
Groundwork for In vitro Activity, Indication, and IND
Erika Matuschek, ESCMID

11:00 a.m. - 11:30 a.m.
NDA Requirements: Clinical Trial Data, Surveillance, Breakpoints
Kevin Krause, Achaogen

11:30 a.m. - 12:00 p.m.
AST Devices, Antibacterial Test Trial vs Clinical Practice
Robin Patel, Mayo Clinic

12:00 p.m. - 12:30 p.m.
Roundtable: Pitfalls in Development

12:30 p.m. – 1:30 p.m.
Lunch

PK-PD Dosing Issues in Special Patient Populations

1:30 p.m. - 2:00 p.m.
Critically Ill Patients versus Healthy Volunteers
Jason Roberts, The University of Queensland

2:00 p.m. - 2:30 p.m.
CLcr of 30-50 vs >120 mL/min: Dosing Issues or Special Populations?
Thomas Lodise, Albany College of Pharmacy and Health Sciences

2:30 p.m. - 3:00 p.m.
Neonates and Infants
Mike Sharland, St. George’s, University of London

3:00 p.m. - 3:30 p.m.
Pediatrics: At the Interface Between Pharmacometrics and Regulatory Science
Gilbert Burckart, Food and Drug Administration

3:45 p.m. - 4:45 p.m.
Coffee Break / Poster Presentations

Global Strategies, Microbiology, PK-PD, and Special Populations

4:30 p.m. - 4:45 p.m.
Platform Research Presentation

4:45 p.m. - 5:00 p.m.
Platform Research Presentation

5:00 p.m. - 5:15 p.m.
Platform Research Presentation

5:45 p.m. – 7:15 p.m. 
Reception (extra fee)

Friday, September 8, 2017

7:30 a.m. – 8:00 a.m.
Light Breakfast

Keynote Lecture
8:00 a.m. - 8:30 a.m.
Finding New Therapeutic Agents: Triumphs and Tragedies
Heinz Moser, Novartis

Understand and Overcome Membrane Barriers of Gram-Negative Bacteria

8:30 a.m. - 9:00 a.m.
Drug Penetration and the Multiple Target Hypothesis: Two Challenges to Antibacterial Discovery
Lynn Silver, LL Silver Consulting, LLC

9:00 a.m. - 9:30 a.m.
Porin Mediated Uptake
Ruben Tommasi, Entasis Therapeutics

9:30 a.m. - 10:00 a.m.
How Much Drug Gets to the Target?
Kyu Rhee, Weill Cornell Medical College

10:00 a.m. - 10:30 a.m.
Outer Membrane Permeabilizer
Aileen Rubio, Spero Therapeutics

10:30 a.m . - 11:00 a.m.
Coffee Break

11:00 a.m. - 11:15 a.m.
Conclusion and Closing of the Conference

11:15 a.m. - 12:00 p.m.
Open Planning Meeting for the 2018 Conference in Europe

 

For questions or comments, please email asm-escmid@asmusa.org

 

TPL_asm2013_ADDITIONAL_INFORMATION

TPL_asm2013_SEARCH

94881